Forge Biologics to Present at Chardan’s 5th Annual Genetic Medicines Manufacturing Summit - Forge Biologics

Forge Biologics to Present at Chardan’s 5th Annual Genetic Medicines Manufacturing Summit


COLUMBUS, Ohio – April 22, 2021 Forge Biologics, a hybrid gene therapy contract manufacturing, and clinical stage therapeutic development company, announced today that it will be presenting at Chardan’s 5th Annual Genetic Medicines Manufacturing Summit, being held virtually April 26-27, 2021.  

Forge Chief Executive Officer, President, and Co-Founder Timothy J. Miller, Ph.D., will be joined by David Dismuke, Ph.D., the company’s Chief Technical Officer, in a fireside chat format to be moderated by Chardan analyst Gbola Amusa on April 26 at 2:30 p.m. The Forge team will also participate in one-on-one meetings during the conference. 

Chardan’s 5th Annual Genetic Medicines Manufacturing Summit features leading companies, academics, and thought leaders focused on advancing genetic medicines.

“We are honored and grateful to be participating at this exclusive event hosted by Chardan during such an exciting time for Forge Biologics, as we continue to grow our team and our facility with our vision focused sharply on significantly advancing gene therapy manufacturing capabilities,” said Dr. Miller.

The virtual event is limited to current or prospective relationships of Chardan, but Forge’s company presentation video will be available to view after the conference on its website at

About Forge Biologics
Forge Biologics is a hybrid gene therapy contract manufacturing and therapeutic development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea into reality.  Forge has a 175,000 ft2 facility in Columbus, Ohio, “The Hearth,” to serve as its headquarters. The Hearth is the home of a custom-designed cGMP facility dedicated to AAV viral vector manufacturing and will host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing.  By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most. For more information, please visit

Media Inquiries
Dan Salvo – Forge Biologics
Director of Communications and Community Development

Business Development
Magdalena Tyrpien – Forge Biologics
Vice President and Head of Business Development

Investor Relations
Christina Perry – Forge Biologics
Vice President, Finance and Operations

Patient, Pediatrician, Genetic Counselors & Family Inquiries
Dr. Maria Escolar – Forge Biologics
Chief Medical Officer


0/5 (0 Reviews)